All In MedTech

FDA Clearance Tracker · K262156

Anti-HCV Next

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Sep 23, 2026

Substantially Equivalent

Time to decision

89 days

Received Jun 26, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K262156
Device name
Anti-HCV Next
Applicant location
Abbott Park, IL
Received
Jun 26, 2026
Decided
Sep 23, 2026
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 866.3169

Every decision under product code MZO

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MZO. The earliest in FDA's data is P980046-S002, decided Apr 12, 2000.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Abbott Laboratories

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.